Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
31 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Santero Therapeutics from Charleroi, company number BE0765790155, closed financial year 2025 with a result of € -2.1 million after tax. For that financial year Santero Therapeutics recorded a gross margin of € 991,461 and equity of € 3.6 million. Compared with financial year 2024, the result moved from € -2.3 million to € -2.1 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 24, 2026.
€ 3.6 million
▲ 44% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -2.1 million
▲ 7 % less loss than in 2024
Profit after tax over the fiscal year.
€ 2.1 million
▼ 2% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -2.1 million.
People and assets in 2025
11.9
▲ 3.5 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.1 million
▲ 55% vs 2024
€ 95,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 225,579
▼ 19% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 176,143
▲ 54% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -74,756 | € 391,750 | € 469,675 | € 991,461 | ▲ 111% |
| Profit after taxes | € -400,715 | € -902,783 | € -2,300,155 | € -2,145,592 | ▲ € 154,563 |
| Equity | € 534,306 | € 752,183 | € 2,527,028 | € 3,631,776 | ▲ 44% |
| Total debts | € 140,423 | € 2,041,100 | € 471,702 | € 519,996 | ▲ 10% |
| Cash | € 446,081 | € 2,396,929 | € 2,144,026 | € 2,106,862 | ▼ 2% |
| Retained profit | € -575,694 | € -1,478,477 | € -3,778,632 | € -2,145,592 | ▲ € 1.6 million |
| Balance sheet total | € 674,729 | € 2,793,283 | € 2,998,730 | € 4,151,772 | ▲ 38% |
| Employees (FTE) | 2.6 | 3.4 | 8.4 | 11.9 | ▲ 3.5 |
Key figures of Santero Therapeutics, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Santero Therapeutics?
What happened at Santero Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Albert Palomer Benet stepped down as director. NBB
- Gokhan Batur stepped down as director. NBB
- François Fontaine stepped down as director. NBB
- SPARAXIS stepped down as director. NBB
- Cédric Govaerts stepped down as director. NBB
- Newton Biocapital II stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 2.1 million. Source: NBB ↗
- Abel Garcia Pino stepped down as director. NBB
In short
From € 400,715 loss in 2022 to € 2.1 million loss in 2025.
Paid € 688 in corporate taxes since 2022.
On average € 83,300 of value added per employee in 2025.
A new publication or filing at Santero Therapeutics? We notify you, reason included.
Follow Santero TherapeuticsDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Newton Biocapital II, SOCIETE FEDERALE DE PARTICIPATIONS ET D'INVESTISSEMENT comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Santero TherapeuticsThe shares are held by Newton Biocapital II (27.7%) and SOCIETE FEDERALE DE PARTICIPATIONS ET D'INVESTISSEMENT (15.8%).
Directors
According to the 2025 annual accounts
François Fontaine
Director
since 2023 · until 2028
Director · represented by Christine Franssen
Also active at: C.P. Bourg, A.M.B., Jean Goldschmidt International, Ateliers Pierre Cerfontaine, Floridienne, Fonderies J. Marichal Ketin et Cie, JUNGLING, MEBF +223 more
since 2023 · until 2028
Albert Palomer Benet
Director
since 2024 · until 2029
Cédric Govaerts
Managing director
since 2023 · until 2028
Abel Garcia Pino
Director
since 2023 · until 2025
Director · represented by TOMOKO ASAOKA
since 2024 · until 2028
Gokhan Batur
Director
since 2024 · until 2029
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue Clément Ader 10
6041 Charleroi
Triomflaan Accès 2 box 206/2
1050 Elsene
Active since 1 December 2021
Rue Granbonpré 11
1435 Mont-Saint-Guibert
Active since 1 September 2023
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 31 companies are registered at this address.
All companies at this address →Brussels South Charleroi BioPark Dev
€ 80,186 gross margin · 2025
ImmunXperts
€ 393,338 gross margin · 2024
LYS MEDICAL
€ -309,203 gross margin · 2025
SPECTRALYS BIOTECH
€ 143,689 gross margin · 2025
ProtonW.be
€ -7,643 gross margin · 2025
+26 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0765.790.155
- VAT number
- BE 0765.790.155
- Registered office
- Rue Clément Ader 10, 6041 Charleroi
- Names & denominations
- Santero Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 29 March 2021
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied